ESC 365 - Glucagon-like peptide 1 receptor agonists & cardiovascular outcomes: What have we learned?

Open Access

Glucagon-like peptide 1 receptor agonists & cardiovascular outcomes: What have we learned?

Session: Exploring the latest evidence of cardiovascular benefits with glucagon-like peptide 1 receptor agonists

Topic: Risk Factors and Prevention

Speaker: Associate Professor M. Cavender (Chapel Hill, US)

Sponsored by Novo Nordisk A/S

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Associate Professor Matthew Cavender

University of North Carolina Hospitals, Chapel Hill (United States of America)

6 presentations

0 follower

3 more presentations in this session

Cardiovascular effects of glucagon-like peptide 1 receptor agonists.

Speaker: Doctor M. Husain (Toronto, CA)

Glucagon-like peptide 1 receptor agonist use in cardiology.

Speaker: Professor M. Petrie (Glasgow, GB)

Live panel discussion.

Access the full session

Exploring the latest evidence of cardiovascular benefits with glucagon-like peptide 1 receptor agonists

Speakers: Associate Professor M. Cavender, Doctor M. Husain, Professor M. Petrie

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources